Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Inborn Errors of Bile Acid Synthesis
Interventions
DRUG

Cholic acid

"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY